Potential urinary and plasma biomarkersof peroxisome proliferation in the rat:: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography

被引:65
作者
Ringeissen, S
Connor, SC
Brown, HR
Sweatman, BC
Hodson, MP
Kenny, SP
Haworth, RI
McGill, P
Price, MA
Aylott, MC
Nunez, DJ
Haselden, JN
Waterfield, CJ
机构
[1] GlaxoSmithKline, Safety Assessment, Ware SG12 ODP, Herts, England
[2] GlaxoSmithKline, Safety Assessment, Res Triangle Pk, NC 27709 USA
[3] GlaxoSmithKline, Stat & Data Sci, Ware SG12 ODP, Herts, England
[4] GlaxoSmithKline, Discovery Med Metab Dis, Res Triangle Pk, NC 27709 USA
关键词
biomarkers; N-methylnicotinamide; N-methyl-4-pyridone-3-carboxamide; biofluid nuclear magnetic resonance spectroscopy; metabonomics; multivariate data analysis; rat plasma; rat urine; peroxisome proliferator-activated receptor; peroxisome; SEMIALDEHYDE DECARBOXYLASE ACMSD; TRYPTOPHAN-NIACIN METABOLISM; NONGENOTOXIC CARCINOGENESIS; NAD(+) BIOSYNTHESIS; ACID TRIGONELLINE; OXIDASE ACTIVITY; NICOTINIC-ACID; FED CLOFIBRATE; LINOLEIC-ACID; HUMAN LIVER;
D O I
10.1080/1354750031000149124
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This study identified two potential novel biomarkers of peroxisome proliferation in the rat. Three peroxisome proliferator-activated receptor (PPAR) ligands, chosen for their high selectivity towards the PPARalpha, -delta and -gamma subtypes, were given to rats twice daily for 7 days at doses known to cause a pharmacological effect or peroxisome proliferation. Fenofibrate was used as a positive control. Daily treatment with the PPARalpha and -delta agonists produced peroxisome proliferation and liver hypertrophy. H-1 nuclear magnetic resonance spectroscopy and multivariate statistical data analysis of urinary spectra from animals given the PPARalpha and -delta agonists identified two new potential biomarkers of peroxisome proliferation - N-methylnicotinamide (NMN) and N-methyl-4-pyridone-3-carboxamide (4PY) - both endproducts of the tryptophan-nicotinamide adenine dinucleotide (NAD(+)) pathway. After 7 days, excretion of NMN and 4PY increased 24- and three-fold, respectively, following high doses of fenofibrate. The correlation between total NMN excretion over 7 days and the peroxisome count was r = 0.87 (r(2) = 0.76). Plasma NMN, measured using a sensitive high performance liquid chromatography method, was increased up to 61-fold after 7 days' treatment with high doses of fenofibrate. Hepatic gene expression of aminocarboxymuconate-semialdehyde decarboxylase (EC 4.1.1.45) was downregulated following treatment with the PPARalpha and -delta agonists. The decrease was up to 11-fold compared with controls in the groups treated with high doses of fenofibrate. This supports the link between increased NMN and 4PY excretion and regulation of the tryptophan-NAD(+) pathway in the liver. In conclusion, NMN, and possibly other metabolites in the pathway, are potential non-invasive surrogate biomarkers of peroxisome proliferation in the rat.
引用
收藏
页码:240 / 271
页数:32
相关论文
共 59 条
[1]   MECHANISTICALLY-BASED HUMAN HAZARD ASSESSMENT OF PEROXISOME PROLIFERATOR-INDUCED HEPATOCARCINOGENESIS [J].
ASHBY, J ;
BRADY, A ;
ELCOMBE, CR ;
ELLIOTT, BM ;
ISHMAEL, J ;
ODUM, J ;
TUGWOOD, JD ;
KETTLE, S ;
PURCHASE, IFH .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1994, 13 :S1-S117
[3]   HEPATIC PEROXISOME PROLIFERATION IN RODENTS AND ITS SIGNIFICANCE FOR HUMANS [J].
BENTLEY, P ;
CALDER, I ;
ELCOMBE, C ;
GRASSO, P ;
STRINGER, D ;
WIEGAND, HJ .
FOOD AND CHEMICAL TOXICOLOGY, 1993, 31 (11) :857-907
[4]   NEW SYNTHESIS OF THE 4-PYRIDONES AND 6-PYRIDONES OF 1-METHYLNICOTINAMIDE AND 1-METHYLNICOTINIC ACID (TRIGONELLINE) [J].
BERNOFSKY, C .
ANALYTICAL BIOCHEMISTRY, 1979, 96 (01) :189-200
[5]  
BROWN RR, 1994, L-TRYPTOPHAN CURRENT PROSPECTS IN MEDICINE AND DRUG SAFETY, P17
[6]   MITOSIS AND HISTOPATHOLOGY IN RAT-LIVER DURING METHYLCLOFENAPATE-INDUCED HYPERPLASIA [J].
BYBEE, A ;
STYLES, JA ;
BECK, SL ;
BLACKBURN, D .
CANCER LETTERS, 1990, 52 (02) :95-100
[7]   NICOTINAMIDE METHYLATION AND HEPATIC ENERGY RESERVE - A STUDY BY LIVER PERFUSION IN-VITRO [J].
CUOMO, R ;
PUMPO, R ;
SARNELLI, G ;
CAPUANO, G ;
BUDILLON, G .
JOURNAL OF HEPATOLOGY, 1995, 23 (04) :465-470
[8]   Evidence for peroxisome proliferator-activated receptor (PPAR)α-independent peroxisome proliferation:: Effects of PPARγ/δ-specific agonists in PPARα-Null mice [J].
DeLuca, JG ;
Doebber, TW ;
Kelly, LJ ;
Kemp, RK ;
Molon-Noblot, S ;
Sahoo, SP ;
Ventre, J ;
Wu, MS ;
Peters, JM ;
Gonzalez, FJ ;
Moller, DE .
MOLECULAR PHARMACOLOGY, 2000, 58 (03) :470-476
[9]  
DEPREZ S, 2003, J PHARMACEUT BIOMED, V30, P1297